Profile data is unavailable for this security.
About the company
PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases. The Company utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002). The Company's VP-001 program is a lead asset for a blinding eye disease of childhood progressed through multiple patient cohorts in the ongoing single ascending dose clinical trial. ADOA is a progressive and blinding eye disease.
- Revenue in AUD (TTM)22.86m
- Net income in AUD-37.73m
- Incorporated2001
- Employees23.00
- LocationPYC Therapeutics LtdHarry Perkins Institute, 6 Verdun StNEDLANDS 6009AustraliaAUS
- Phone+61 86151-0992
- Fax+61 89489-7700
- Websitehttps://pyctx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arovella Therapeutics Ltd | 155.73k | -8.75m | 200.69m | 14.00 | -- | 17.78 | -- | 1,288.68 | -0.0093 | -0.0093 | 0.0002 | 0.0107 | 0.0166 | -- | 30.42 | -- | -93.26 | -78.61 | -116.36 | -96.29 | 100.00 | 51.81 | -5,616.16 | -2,126.97 | -- | -1,012.45 | 0.00 | -- | -64.27 | -34.07 | 14.10 | -- | -37.76 | -- |
| Dimerix Ltd | 583.48k | -17.08m | 217.36m | 0.00 | -- | 11.80 | -- | 372.52 | -0.0373 | -0.0373 | 0.0013 | 0.0331 | 0.0234 | -- | 0.0612 | -- | -68.53 | -71.97 | -98.37 | -113.16 | -- | -- | -2,926.42 | -8,332.83 | -- | -- | 0.0082 | -- | 1,485.97 | 100.27 | -23.71 | -- | 17.99 | -- |
| Race Oncology Ltd | 832.58k | -13.82m | 259.97m | -- | -- | 14.18 | -- | 312.25 | -0.0839 | -0.0839 | 0.0051 | 0.1075 | 0.0355 | -- | 0.9201 | -- | -58.97 | -46.49 | -63.04 | -48.68 | -- | -- | -1,659.82 | -2,995.74 | -- | -- | 0.00 | -- | 40.68 | 116.86 | -39.26 | -- | -- | -- |
| Imugene Ltd | 0.00 | -149.68m | 357.04m | 0.00 | -- | 2.97 | -- | -- | -0.0211 | -0.0211 | 0.00 | 0.0162 | 0.00 | -- | -- | -- | -85.91 | -44.42 | -95.62 | -47.46 | -- | -- | -- | -- | -- | -- | 0.0053 | -- | -- | -- | -294.78 | -- | 136.28 | -- |
| Immutep Ltd | 119.62k | -42.72m | 450.92m | 19.00 | -- | 2.40 | -- | 3,769.57 | -0.0353 | -0.0353 | 0.0001 | 0.1293 | 0.0007 | -- | 0.655 | -- | -24.48 | -31.68 | -25.99 | -33.91 | -- | -- | -35,710.27 | -1,829.94 | -- | -- | 0.0083 | -- | -37.61 | -54.35 | -7.07 | -- | 86.40 | -- |
| PYC Therapeutics Ltd | 22.86m | -37.73m | 909.89m | 23.00 | -- | 11.44 | -- | 39.81 | -0.0094 | -0.0094 | 0.0057 | 0.017 | 0.356 | -- | 97.03 | -- | -59.36 | -45.92 | -69.52 | -52.18 | -- | -- | -166.75 | -167.45 | -- | -69.18 | 0.0135 | -- | 43.85 | 882.22 | -65.54 | -- | -7.67 | -- |
| Opthea Ltd | 189.47k | -334.72m | 1.01bn | 5.00 | -- | -- | -- | 5,328.05 | -0.525 | -0.525 | 0.0003 | -0.1056 | 0.0009 | -- | 0.0136 | -- | -153.25 | -112.75 | -215.25 | -134.33 | 100.00 | -- | -176,660.10 | -113,428.10 | -- | -5.08 | 1.61 | -- | 15.00 | 1.86 | -54.53 | -- | 20.99 | -- |
| Mesoblast Ltd | 8.97m | -133.67m | 1.67bn | 73.00 | -- | 2.28 | -- | 185.85 | -0.1332 | -0.1332 | 0.0091 | 0.6397 | 0.0088 | -- | 3.21 | 122,871.60 | -13.14 | -12.62 | -14.38 | -13.97 | -166.30 | -109.14 | -1,490.28 | -692.63 | -- | -3.54 | 0.1984 | -- | -21.32 | -18.80 | -7.41 | -- | -0.5802 | -- |
| Clarity Pharmaceuticals Ltd | 0.00 | -42.32m | 2.40bn | -- | -- | 15.93 | -- | -- | -0.1541 | -0.1541 | 0.00 | 0.4694 | 0.00 | -- | -- | -- | -36.56 | -- | -39.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -72.03 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Wilson Asset Management (International) Pty Ltd.as of 30 Jun 2024 | 15.87m | 0.36% |
| Eagle Bay Advisors LLCas of 30 Sep 2024 | 40.00k | 0.00% |
